0000000000088162

AUTHOR

Emanuel Christ

0000-0002-5604-4606

showing 7 related works from this author

Post-prandial alterations in LDL size and subclasses in patients with growth hormone deficiency

2008

Abstract Objective Several studies have suggested that lipoproteins generated during the post-prandial phase are highly atherogenic, with modifications in low-density lipoproteins (LDL) size and density. In the present study we assessed post-prandial variations in LDL size and subclasses in patients with growth hormone deficiency (GHD). Design We studied in 12 hypopituitary patients with GHD and 10 healthy control subjects matched for gender, age and body mass index (BMI) post-prandial variations after a standardized meal consisting of 35% fat, 45% carbohydrate and 20% of protein (Clinutren Mix ® , Nestle) and containing calories corresponding to 1/3 of estimated basal metabolic rate. Blood…

AdultMalemedicine.medical_specialtyCalorieEndocrinology Diabetes and Metabolism10265 Clinic for Endocrinology and Diabetology610 Medicine & healthPilot ProjectsHypopituitarismSubclassGrowth hormone deficiencyEndocrinologyInternal medicinemedicineHumansLipoproteinGel electrophoresisMealbusiness.industryMiddle AgedCarbohydratePost-prandialPostprandial Periodmedicine.diseaseSmall dense LDL1310 EndocrinologyLipoproteins LDL2712 Endocrinology Diabetes and MetabolismEndocrinologyCase-Control StudiesGrowth HormoneBasal metabolic rateGrowth hormone deficiencyFemalelipids (amino acids peptides and proteins)businessBody mass indexGrowth Hormone & IGF Research
researchProduct

Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2…

2008

To assess the effects of pioglitazone and rosiglitazone on fasting and postprandial low-density lipoprotein (LDL) size and subclasses in patients with Type 2 diabetes.Nine Type 2 diabetic patients (age 61 +/- 10 years, body mass index 30 +/- 5 kg/m(2), glycosylated hemoglobin [HbA1c] 7.5 +/- 0.5%) were randomized in a crossover trial to rosiglitazone 4 mg b.i.d. or pioglitazone 45 mg/day for 12 weeks with an 8-week wash-out period. LDL size and subclasses were determined by non-denaturing polyacrylamide gradient gel electrophoresis. A standardized breakfast was served and variables were assessed after 3 and 6 h.HbA1c, insulin sensitivity (as assessed by the homeostasis model assessment) and…

Malemedicine.medical_specialtyType 2 diabetesRosiglitazonechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)Prospective StudiesTriglyceridesPharmacologyGlycated HemoglobinCross-Over StudiesTriglyceridePioglitazoneCholesterolbusiness.industryGeneral MedicineCholesterol LDLFastingGlucose Tolerance TestMiddle Agedmedicine.diseasePostprandial PeriodLipoproteins LDLPostprandialEndocrinologychemistryDiabetes Mellitus Type 2Low-density lipoproteindense LDL diabetes LDL size pioglitazone postprandial rosiglitazoneElectrophoresis Polyacrylamide GelFemaleThiazolidinedionesbusinessRosiglitazonePioglitazonemedicine.drug
researchProduct

COMPARATIVE EFFECTS OF ROSIGLITAZONE AND PIOGLITAZONE ON FASTING AND POSTPRANDIAL LDL-SIZE AND SUBCLASSES IN PATIENTS WITH TYPE-2 DIABETES

2008

medicine.medical_specialtybusiness.industryGeneral MedicineType 2 diabetesmedicine.diseaseFasting glucosePostprandialEndocrinologyInternal medicineInternal Medicinerosiglitazone pioglitazone fasting glucose postprandial glucose LDL type-2 diabetesMedicineIn patientCardiology and Cardiovascular MedicinebusinessRosiglitazonePioglitazonemedicine.drugAtherosclerosis Supplements
researchProduct

The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

2008

Diabetic dyslipidemia is typically characterized by an increase in plasma triglycerides, a decrease in high-density lipoprotein cholesterol and a concomitant increase in atherogenic small dense low-density lipoproteins. Thiazolidindiones are able to lower the levels of fasting glucose and glycated hemoglobin significantly by improving insulin sensitivity, as well as improving some aspects of diabetic dyslipidemia: total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol tend to increase while triglycerides are generally decreased.This paper reviewed the effects of pioglitazone and rosiglitazone on atherogenic diabetic dyslipidemia, in particular on sma…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthType 2 diabetesRosiglitazonechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicine2736 Pharmacology (medical)HumansHypoglycemic AgentsPharmacology (medical)Clinical significancecardiovascular risk dense low-density lipoprotein diabetes low-density lipoprotein size pioglitazone rosiglitazone smallTriglyceridesDyslipidemiasPharmacologyAtherogenic dyslipidemiaPioglitazonebusiness.industryThiazolidindionesAtherogenic dyslipidemiaGeneral Medicinemedicine.diseaseLipoproteins LDLEndocrinology3004 PharmacologychemistryDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)ThiazolidinedionesGlycated hemoglobinbusinessRosiglitazoneLipoproteins HDLPioglitazoneBiomarkersmedicine.drugLipoprotein
researchProduct

Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-t…

2007

Objective: Patients with growth hormone deficiency (GHD) have increased cardiovascular risk and may show elevated triglyceride and reduced high density lipoprotein (HDL) cholesterol concentrations, two lipid abnormalities usually accompanied by increased small dense LDL in the ‘atherogenic lipoprotein phenotype’ (ALP). In the present study, we directly investigated (1) whether hypopituitary patients with GHD have increased small dense LDL; (2) whether growth hormone replacement therapy (GHRT) beneficially impact on such particles; (3) the prevalence of ALP in GHD and GHRT patients. Design and methods: In 14 hypopituitary patients with GHD (44 ± 13 years, body mass index (BMI) 27 ± 3) before…

AdultMalemedicine.medical_specialtyTime FactorsArteriosclerosisHormone Replacement TherapyEndocrinology Diabetes and MetabolismBiologyHypopituitarismGrowth hormone deficiencychemistry.chemical_compoundEndocrinologyInternal medicinemedicineHumansIn patientInsulin-Like Growth Factor ITriglyceridesTriglycerideHuman Growth HormoneCholesterolVascular diseaseCholesterol HDLGeneral MedicineMiddle AgedAtherogenic lipoprotein phenotypemedicine.diseaseLipoproteins LDLCholesterolTreatment OutcomeEndocrinologyAtheromachemistryLow-density lipoproteinElectrophoresis Polyacrylamide GelFemalelipids (amino acids peptides and proteins)European Journal of Endocrinology
researchProduct

40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

2004

0303 health sciencesmedicine.medical_specialtybusiness.industryEASDEndocrinology Diabetes and MetabolismHuman physiologymedicine.disease03 medical and health sciences0302 clinical medicineDiabetes mellitusFamily medicineInternal MedicineMedicinebusiness030217 neurology & neurosurgery030304 developmental biology
researchProduct

The role of elevated growth hormone on the increased atherosclerosis in patients with acromegaly.

2012

medicine.medical_specialtybusiness.industryHuman Growth HormoneMEDLINEGrowth Hormone Atherosclerosis AcromegalyBioinformaticsmedicine.diseaseGrowth hormoneAtherosclerosisText miningEndocrinologyRisk FactorsInternal medicineAcromegalyAcromegalymedicineHumansIn patientInsulin ResistanceInsulin-Like Growth Factor ICardiology and Cardiovascular MedicinebusinessAngiology
researchProduct